Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06892691

Pleuroscopy First Versus Thoracentesis First in Patients With Suspected Malignant Pleural Effusions

This is a randomized control trial of patients with suspected malignant pleural effusions to compare whether patients who have a thoracentesis or pleuroscopy (pleural biopsy) obtain an adequate biopsy, achieve a diagnosis, and begin cancer-directed therapy faster.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Mount Sinai Hospital, New York, United States

Loading trial locations.

About this study

This is a randomized control trial of patients with suspected malignant pleural effusions comparing patients who undergo either pleuroscopy or thoracentesis as the first diagnostic test. Both procedures are considered standard of care for this diagnosis but it is unknown which one provides more adequate biopsy samples and achieves faster diagnosis and shorter time to oncologic treatment. Currently, most patients undergo thoracentesis first and, if this is inadequate for diagnosis, they then undergo pleuroscopy for further biopsy samples. This study seeks to assess whether patients who undergo pleuroscopy as the first test obtain adequate biopsy samples and a faster path to further oncologic care compared to patients who undergo thoracentesis first. Patients will be recruited and randomized in a 1:1 manner.

Ultrasound is routinely used prior to the procedure and a chest x-ray is done after the procedure. Any other imaging will be determined by clinic need only. No imaging will be done for research purposes. No additional samples will be collected other than what is necessary for diagnostic purposes. In patients who have a non-diagnostic thoracentesis, the participants will be referred for pleuroscopy as the next diagnostic step. In the rare case that pleuroscopy does not achieve adequate diagnosis, the next step would be a liquid biopsy (non-invasive serologic testing for oncologic markers.) The need for liquid biopsy in participants in this study will be determined on a case-by-case basis depending on the clinical concern for malignancy.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Referral for diagnostic pleural procedure.
  • Age ≥ 18 years.
  • Suspected malignant pleural effusion (Suggestive radiologic appearance (based on computed tomography or positron emission tomography) OR suspected cancer with associated effusion.)

Exclusion criteria

  • Inability to provide informed consent.
  • Needs emergent drainage.
  • Pleural effusion is known to be malignant.
  • Suspected transudative, infectious or inflammatory effusion etiology.
  • Having prior inconclusive/non-diagnostic thoracentesis or pleuroscopy.
  • Patient is deemed by the clinical team to be more appropriate for VATS biopsy.
  • Terminally ill patients in whom a diagnosis will not change management, or who is unlikely to be a candidate for oncological treatment due to significant comorbidities.
  • Pregnancy

Treatment and study plan

Pleuroscopy first

Procedure

Pleuroscopies are performed under moderate sedation with local anesthesia. Through a 1-cm incision a camera is introduced into the pleural space and the space is inspected after draining all fluid. Targeted biopsies under direct visualization are obtained using forceps. The aspirated fluid and biopsies obtained are sent to the cytology and pathology laboratories for analysis.

Thoracentesis first

Procedure

Thoracenteses are performed under local anesthesia with the insertion of a 5-8Fr catheter into the pleural space. The aspirated fluid obtained is sent to the cytology laboratory for analysis.

Primary outcomes

  1. Proportion of biopsies adequate for definitive diagnosis

    Time frame: 6 months

    Proportion of biopsies adequate for definitive diagnosis

Secondary outcomes

  1. Time from initial visit with pulmonologist to procedure

    Time frame: 6 months

    Time from initial visit with pulmonologist to procedure

  2. Time from initial procedure to diagnosis

    Time frame: 6 months

    Time from initial procedure to diagnosis

  3. Time from initial visit with pulmonologist to diagnosis

    Time frame: 6 months

    Time from initial visit with pulmonologist to diagnosis

  4. Time from initial visit with pulmonologist to seeing oncologist

    Time frame: 6 months

    Time from initial visit with pulmonologist to seeing oncologist

  5. Time from initial visit with pulmonologist to starting treatment

    Time frame: 6 months

    Time from initial visit with pulmonologist to starting treatment

  6. Time from seeing oncologist to starting treatment

    Time frame: 6 months

    Time from seeing oncologist to starting treatment

  7. Frequency of procedure-related complications

    Time frame: 6 months

    Frequency of procedure-related complications

  8. Frequency of additional diagnostic testing

    Time frame: 6 months

    Frequency of additional diagnostic testing

Study contacts

Contact information is provided by the study sponsor or research team.

Udit Chaddha, MBBS

CONTACT

[email protected]

212-241-5900

Sponsors and collaborators

Lead sponsor

Icahn School of Medicine at Mount Sinai

Other

Registry information

Acronym: PERFECT-MPE

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Mar 25, 2025
Registry last updated
Feb 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.